| case report | Q2782326 |
| scholarly article | Q13442814 |
| P50 | author | Brigitte Royer-Pokora | Q43376295 |
| P2093 | author name string | Jaume Mora | |
| Carmen de Torres | |||
| Noelia Perez | |||
| Constanze Uschkereit | |||
| Maike Küff | |||
| P2860 | cites work | WT-1 is required for early kidney development | Q28512266 |
| Frequent association of beta-catenin and WT1 mutations in Wilms tumors. | Q33927092 | ||
| A clinical overview of WT1 gene mutations | Q34738955 | ||
| CTNNB1 mutations and overexpression of Wnt/beta-catenin target genes in WT1-mutant Wilms' tumors | Q35103587 | ||
| Correlation between a specific Wilms tumour suppressor gene (WT1) mutation and the histological findings in Wilms tumour (WT). | Q35559794 | ||
| A WT1 exon 1 mutation in a child diagnosed with Denys-Drash syndrome | Q35926983 | ||
| Correlation of germ-line mutations and two-hit inactivation of the WT1 gene with Wilms tumors of stromal-predominant histology | Q36108223 | ||
| Codon 45 of the beta-catenin gene, a specific mutational target site of Wilms' tumor | Q44143077 | ||
| Myogenesis in Wilms' tumors is associated with mutations of the WT1 gene and activation of Bcl-2 and the Wnt signaling pathway | Q48013596 | ||
| Mutational activation of the beta-catenin proto-oncogene is a common event in the development of Wilms' tumors | Q57413414 | ||
| Twenty-four new cases of WT1 germline mutations and review of the literature: genotype/phenotype correlations for Wilms tumor development | Q80103785 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | patient | Q181600 |
| P304 | page(s) | 393-396 | |
| P577 | publication date | 2007-06-01 | |
| P1433 | published in | Journal of Medical Genetics | Q14640281 |
| P1476 | title | Different CTNNB1 mutations as molecular genetic proof for the independent origin of four Wilms tumours in a patient with a novel germ line WT1 mutation | |
| P478 | volume | 44 |
| Q37256912 | An integrated genome screen identifies the Wnt signaling pathway as a major target of WT1. |
| Q38675275 | Bilateral Wilms tumour: a review of clinical and molecular features |
| Q51739895 | Chemotherapy and terminal skeletal muscle differentiation in WT1-mutant Wilms tumors. |
| Q47670734 | Clinical relevance of mutations in the Wilms tumor suppressor 1 gene WT1 and the cadherin-associated protein beta1 gene CTNNB1 for patients with Wilms tumors: results of long-term surveillance of 71 patients from International Society of Pediatric O |
| Q36200428 | Clinically relevant subsets identified by gene expression patterns support a revised ontogenic model of Wilms tumor: a Children's Oncology Group Study |
| Q36026373 | Establishment of a Conditionally Immortalized Wilms Tumor Cell Line with a Homozygous WT1 Deletion within a Heterozygous 11p13 Deletion and UPD Limited to 11p15. |
| Q37998422 | Genetics of pediatric renal tumors |
| Q26829595 | Is Wilms tumor a candidate neoplasia for treatment with WNT/β-catenin pathway modulators?--A report from the renal tumors biology-driven drug development workshop |
| Q37940867 | WT1 in disease: shifting the epithelial-mesenchymal balance. |
| Q92757147 | Wilm's tumor 1 promotes memory flexibility |
| Q39747265 | Wilms tumor cells with WT1 mutations have characteristic features of mesenchymal stem cells and express molecular markers of paraxial mesoderm |
| Q37866140 | Wilms tumor--a renal stem cell malignancy? |
Search more.